Media coverage about Aralez Pharmaceuticals (NASDAQ:ARLZ) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.182581911901 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at $1.48 on Friday. The company has a debt-to-equity ratio of 4.64, a quick ratio of 0.92 and a current ratio of 1.00. Aralez Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $5.17.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its earnings results on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.02. The firm had revenue of $24.30 million for the quarter, compared to the consensus estimate of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company’s revenue was up 78.7% on a year-over-year basis. During the same period last year, the firm posted ($0.32) EPS. equities research analysts forecast that Aralez Pharmaceuticals will post -1.54 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/aralez-pharmaceuticals-arlz-receiving-somewhat-positive-news-coverage-analysis-shows/1755692.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.